CN101321524A - 雌激素β激动剂的新用途 - Google Patents
雌激素β激动剂的新用途 Download PDFInfo
- Publication number
- CN101321524A CN101321524A CNA2005800434508A CN200580043450A CN101321524A CN 101321524 A CN101321524 A CN 101321524A CN A2005800434508 A CNA2005800434508 A CN A2005800434508A CN 200580043450 A CN200580043450 A CN 200580043450A CN 101321524 A CN101321524 A CN 101321524A
- Authority
- CN
- China
- Prior art keywords
- carbon atom
- alkyl
- halogen
- alkenyl
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63714404P | 2004-12-17 | 2004-12-17 | |
| US60/637,144 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101321524A true CN101321524A (zh) | 2008-12-10 |
Family
ID=36143266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800434508A Pending CN101321524A (zh) | 2004-12-17 | 2005-12-15 | 雌激素β激动剂的新用途 |
Country Status (20)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1984028A2 (en) * | 2006-02-14 | 2008-10-29 | Wyeth a Corporation of the State of Delaware | Aqueous pharmaceutical formulations of er selective ligands |
| WO2010105035A2 (en) * | 2009-03-11 | 2010-09-16 | University Of South Florida | Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure |
| US10149982B2 (en) | 2009-03-11 | 2018-12-11 | University Of South Florida | Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment |
| US10758496B2 (en) * | 2014-09-02 | 2020-09-01 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| WO2018183800A1 (en) * | 2017-03-30 | 2018-10-04 | Marquette University | Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990078A (en) * | 1995-07-14 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Means of increasing estrogen receptor levels in neural tissue |
| FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| WO1998021946A1 (en) * | 1996-11-18 | 1998-05-28 | Internutria, Inc. | Composition and treatment for persistent reproductive transition symptoms |
| US20040092010A1 (en) * | 2002-04-15 | 2004-05-13 | Ariel Ruiz I Altaba | Method of proliferating and inducing brain stem cells to differentiate to neurons |
| TR200102992T2 (tr) * | 1999-04-16 | 2004-12-21 | Astrazeneca Ab | ß östrojen reseptörü ligandları. |
| JP2004515496A (ja) * | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール治療剤 |
| WO2002051821A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
| US20030096264A1 (en) * | 2001-06-18 | 2003-05-22 | Psychiatric Genomics, Inc. | Multi-parameter high throughput screening assays (MPHTS) |
| DE60116109T2 (de) * | 2001-11-07 | 2006-09-07 | Schering Ag | In vitro Screening nach Liganden des Östrogenrezeptors |
| UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| TWI306450B (en) * | 2001-12-13 | 2009-02-21 | Wyeth Corp | Substituted phenyl naphthalenes as estrogenic agents |
| TW200301107A (en) * | 2001-12-13 | 2003-07-01 | Wyeth Corp | Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents |
| US6774248B2 (en) * | 2001-12-18 | 2004-08-10 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
| WO2004026290A1 (en) * | 2002-09-19 | 2004-04-01 | Merck & Co., Inc. | Method for treating depression and/or anxiety |
| CL2004000985A1 (es) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
| US7157492B2 (en) * | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| JP2008505095A (ja) * | 2004-07-01 | 2008-02-21 | ワイス | エストロゲンリガンドとしての四環式化合物 |
-
2005
- 2005-12-15 RU RU2007120254/14A patent/RU2007120254A/ru not_active Application Discontinuation
- 2005-12-15 EP EP05854149A patent/EP1824478A2/en not_active Withdrawn
- 2005-12-15 MX MX2007007347A patent/MX2007007347A/es unknown
- 2005-12-15 US US11/304,037 patent/US20060135574A1/en not_active Abandoned
- 2005-12-15 KR KR1020077013666A patent/KR20070086329A/ko not_active Withdrawn
- 2005-12-15 AR ARP050105297A patent/AR051844A1/es unknown
- 2005-12-15 TW TW094144391A patent/TW200637545A/zh unknown
- 2005-12-15 AU AU2005316561A patent/AU2005316561A1/en not_active Abandoned
- 2005-12-15 CN CNA2005800434508A patent/CN101321524A/zh active Pending
- 2005-12-15 BR BRPI0519111-4A patent/BRPI0519111A2/pt not_active IP Right Cessation
- 2005-12-15 PA PA20058656601A patent/PA8656601A1/es unknown
- 2005-12-15 CA CA002590258A patent/CA2590258A1/en not_active Abandoned
- 2005-12-15 JP JP2007546887A patent/JP2008524236A/ja active Pending
- 2005-12-15 GT GT200500370A patent/GT200500370A/es unknown
- 2005-12-15 WO PCT/US2005/045375 patent/WO2006065968A2/en not_active Ceased
-
2006
- 2006-01-03 PE PE2006000026A patent/PE20061113A1/es not_active Application Discontinuation
-
2007
- 2007-05-24 NO NO20072658A patent/NO20072658L/no not_active Application Discontinuation
- 2007-05-31 IL IL183604A patent/IL183604A0/en unknown
- 2007-06-14 NI NI200700152A patent/NI200700152A/es unknown
- 2007-06-15 ZA ZA200705103A patent/ZA200705103B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0519111A2 (pt) | 2008-12-23 |
| PA8656601A1 (es) | 2006-12-07 |
| AR051844A1 (es) | 2007-02-14 |
| WO2006065968A8 (en) | 2008-09-12 |
| IL183604A0 (en) | 2007-10-31 |
| AU2005316561A1 (en) | 2006-06-22 |
| MX2007007347A (es) | 2007-07-13 |
| RU2007120254A (ru) | 2009-01-27 |
| NO20072658L (no) | 2007-09-12 |
| WO2006065968A2 (en) | 2006-06-22 |
| PE20061113A1 (es) | 2006-11-06 |
| CA2590258A1 (en) | 2006-06-22 |
| WO2006065968A3 (en) | 2008-04-10 |
| TW200637545A (en) | 2006-11-01 |
| GT200500370A (es) | 2006-07-13 |
| NI200700152A (es) | 2008-06-17 |
| KR20070086329A (ko) | 2007-08-27 |
| JP2008524236A (ja) | 2008-07-10 |
| EP1824478A2 (en) | 2007-08-29 |
| ZA200705103B (en) | 2009-11-25 |
| US20060135574A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101939017B (zh) | 大麻素在与抗精神病药物组合中的用途 | |
| KR101733247B1 (ko) | 외상 후 스트레스 장애를 치료하기 위한 테트라하이드로퀴놀린 유도체 | |
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| CN115778931A (zh) | 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱 | |
| WO2017213977A1 (en) | Methods and compositions for the treatment of trauma and stressor-related disorders | |
| KR20200038481A (ko) | 스트레스-관련 장애를 치료하기 위한 조성물 | |
| EP3043799A1 (en) | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease | |
| WO2025170990A1 (en) | Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor | |
| EP2010174A2 (en) | Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression | |
| US20210106592A1 (en) | Methods and compositions for the treatment of traumatic brain injury (tbi) and related disorders | |
| US20060135574A1 (en) | Novel uses for estrogen beta agonists | |
| JP2021505668A (ja) | 併用療法(睡眠障害およびcns障害)において使用するためのnmda受容体モジュレーター(ラパスチネル)の組合せ | |
| KR20210014164A (ko) | 히스타민-3 수용체 역작용제에 의한 치료 방법 | |
| US20190022224A1 (en) | Compositions And Methods For Treating Stress-Related Disorders | |
| CN111973615A (zh) | 一种治疗躁狂型精神障碍及精神分裂症的药物 | |
| JP2009235069A (ja) | 3’,5−ジ−2−プロペニル−(1,1’−ビフェニル)−2,4’−ジオールを有効成分として含有する視神経障害の予防又は治療剤 | |
| US20230381195A1 (en) | Methods and compositions for the treatment of traumatic brain injury (tbi) and related disorders | |
| WO2024226995A1 (en) | Compositions and methods for treating post-traumatic stress disorder | |
| WO2026096783A2 (en) | Compositions and methods for treating post-traumatic stress disorder | |
| WO2009137531A2 (en) | Compositions and methods related to action of low dosages of doxepin on the h1 and 5-ht2a receptors | |
| KR20010029658A (ko) | 뇌의 아세틸콜린 방출 증강제 | |
| TW202519202A (zh) | 3-[(苯並[d][1,3]二氧戊環-4-基)-氧基]-3-芳基丙胺類化合物在製備治療性功能障礙的藥物中的用途 | |
| KR20200099153A (ko) | 외상 후 증후군 장애의 치료 | |
| EA047023B1 (ru) | Композиции и способы лечения расстройств, связанных со стрессом | |
| HK40015213A (en) | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20081210 |